vidaza
bristol-myers squibb pharma eeig - azasitidín - myelodysplastic syndromes; leukemia, myelomonocytic, chronic; leukemia, myeloid, acute - Æxlishemjandi lyf - vidaza is indicated for the treatment of adult patients who are not eligible for haematopoietic stem cell transplantation (hsct) with: intermediate 2 and high-risk myelodysplastic syndromes (mds) according to the international prognostic scoring system (ipss),chronic myelomonocytic leukaemia (cmml) with 10 29 % marrow blasts without myeloproliferative disorder,acute myeloid leukaemia (aml) with 20 30 % blasts and multi-lineage dysplasia, according to world health organisation (who) classification. vidaza is indicated for the treatment of adult patients aged 65 years or older who are not eligible for hsct with aml with >30% marrow blasts according to the who classification.
azacitidine celgene
celgene europe bv - azasitidín - myelodysplastic syndromes; leukemia, myelomonocytic, chronic; leukemia, myeloid, acute - Æxlishemjandi lyf - azacitidine celgene is indicated for the treatment of adult patients who are not eligible for haematopoietic stem cell transplantation (hsct) with:intermediate 2 and high-risk myelodysplastic syndromes (mds) according to the international prognostic scoring system (ipss),chronic myelomonocytic leukaemia (cmml) with 10 29 % marrow blasts without myeloproliferative disorder,acute myeloid leukaemia (aml) with 20 30 % blasts and multi-lineage dysplasia, according to world health organisation (who) classification,aml with >30% marrow blasts according to the who classification.
azacitidine mylan
mylan ireland limited - azasitidín - myelodysplastic syndromes; leukemia, myelomonocytic, chronic; leukemia, myeloid, acute - Æxlishemjandi lyf - azacitidine mylan is indicated for the treatment of adult patients who are not eligible for haematopoietic stem cell transplantation (hsct) with:intermediate 2 and high risk myelodysplastic syndromes (mds) according to the international prognostic scoring system (ipss),chronic myelomonocytic leukaemia (cmml) with 10 29% marrow blasts without myeloproliferative disorder,acute myeloid leukaemia (aml) with 20 30% blasts and multi lineage dysplasia, according to world health organisation (who) classification,aml with > 30% marrow blasts according to the who classification.
quetiapin medical valley forðatafla 300 mg
medical valley invest ab - quetiapinum fúmarat - forðatafla - 300 mg
quetiapin medical valley forðatafla 150 mg
medical valley invest ab - quetiapinum fúmarat - forðatafla - 150 mg
quetiapin medical valley forðatafla 50 mg
medical valley invest ab - quetiapinum fúmarat - forðatafla - 50 mg
quetiapin medical valley forðatafla 200 mg
medical valley invest ab - quetiapinum fúmarat - forðatafla - 200 mg
quetiapin medical valley forðatafla 400 mg
medical valley invest ab - quetiapinum fúmarat - forðatafla - 400 mg
cozaar comp forte filmuhúðuð tafla 100/25 mg
n.v. organon* - losartanum kalíum; hydrochlorothiazidum inn - filmuhúðuð tafla - 100/25 mg
cozaar comp filmuhúðuð tafla 50+12,5 mg
n.v. organon* - losartanum kalíum; hydrochlorothiazidum inn - filmuhúðuð tafla - 50+12,5 mg